Compare Enovix Corporation (ENVX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Enovix Corporation trades at $2.46 (market cap $549.72M), while Recursion Pharmaceuticals Inc trades at $4.41 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.9× Enovix Corporation's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| ENVX | RXRX | |
|---|---|---|
Market Cap | $549.72M | $2.14B |
Volume | 6,635,687 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $13.19 | $6.79 |
52-Week Low | $2.50 | $2.84 |
Typical Hold Time | 11 Days | 23 Days |
Enterprise Value | $611.42M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.46, down 3.53% on the day, with technical indicators signaling a bearish trend. The company reported a net loss of $156.74 million in 2025, with revenue of $31.82 million, and continues to burn cash, though it has beaten EPS estimates in recent quarters. Recent news includes CEO transition and expansion of battery manufacturing capacity.
Despite consistent EPS beats, ENVX faces significant financial challenges with negative margins and cash burn. Analyst consensus is bullish with a $10.75 price target, but high execution risk and leadership changes pose threats to near-term stability and long-term growth prospects.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
